Integrative Strategies for Better Living from Insulin Resistance

Explore effective integrative strategies for insulin resistance to manage your health and improve your lifestyle.

Introduction to Our Discussion on Metabolic Health

Welcome to Health Voice 360. I am Dr. Alexander Jimenez, and I am honored to guide you through a deeply scientific and clinically relevant exploration of one of the most pervasive health challenges of our time: insulin resistance. As a healthcare provider with dual credentials as a Doctor of Chiropractic (DC) and a Family Nurse Practitioner (FNP-APRN), I have dedicated my career to bridging foundational physiological principles and practical, patient-centered care. My clinical observations, available through our platform, consistently highlight a critical disconnect: the conventional approach to managing metabolic dysfunction often falls short because it addresses symptoms rather than the underlying cellular and mitochondrial crises. This post aims to correct that by moving beyond simplistic dietary advice and exploring the complex biological mechanisms that govern metabolic health. We will dismantle the prevailing myths surrounding insulin resistance, particularly the notion that it is merely a consequence of poor diet or excess weight that can be fixed with dietary changes alone. Instead, we will reframe it as a complex state of cellular deafness and metabolic inflexibility, a condition deeply rooted in years, often decades, of chronic hyperinsulinemia that has systematically damaged our cellular machinery.

In the comprehensive discussion that follows, we’ll take a deep dive into the cell to understand why conventional strategies often fail. We’ll start by dissecting the physiological reasons behind the persistence of insulin resistance even when patients adopt stringent low-carb, ketogenic, or carnivore diets. You will learn why glycogen-laden muscles refuse to take up more fuel, and how a fatty, inflamed liver becomes a rogue glucose factory, continuously producing sugar through gluconeogenesis regardless of what you eat. We will explore the critical role of visceral fat and how its mobilization is a prerequisite for “unclogging” the liver and restoring its sensitivity to insulin. We’ll then pivot to the diagnostic tools we use, exposing the profound limitations of the standard HbA1c test, which can paint a deceptively normal picture. Meanwhile, the pancreas works itself to death, flooding the body with insulin. I will explain why the HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) is a far superior metric for assessing true metabolic health, providing an early warning signal long before blood sugar levels begin to rise.

Our exploration will focus on groundbreaking, evidence-based interventions that target the root causes of insulin resistance: mitochondrial dysfunction and cellular inflammation. We will unravel the science behind NAD+ (Nicotinamide Adenine Dinucleotide), a vital cofactor for cellular energy and repair that becomes depleted in states of hyperinsulinemia. I will introduce you to 5-amino-1MQ, a compound research shows can replenish NAD+ levels, and we will review a pivotal 2023 study in Cell Metabolism demonstrating its ability to improve insulin sensitivity significantly. We will also examine the latest pharmaceutical advances, such as retatrutide, and discuss a 2024 study in The Lancet highlighting its potential to induce full insulin independence in a significant portion of people with type 2 diabetes. We will also highlight the mitochondrial-derived peptide MOTS-c, referencing a 2018 study on its powerful effects on glucose tolerance and its unique ability not only to enhance metabolic flexibility but to build new, healthier mitochondria—a process known as mitohormesis. Finally, I will synthesize these advanced concepts into a practical, actionable protocol I call “Strategic Carnivore.” This is not just another diet; it is a metabolic strategy designed to restore cellular function systematically. I will provide a detailed daily audit, explaining how to use a continuous glucose monitor (CGM) to interpret your body’s real-time feedback, assess GLUT4 transporter function, and determine whether your mitochondria are successfully transitioning to fat oxidation. This post is my playbook, shared freely to empower you with the knowledge to reclaim your metabolic health from the inside out.

Unraveling the Paradox: Why Diets Alone Often Fail to Reverse Insulin Resistance

As a clinician on the front lines of metabolic health, one of the most common and frustrating scenarios I encounter is patients who do everything “right” by conventional wisdom, yet their health remains stalled. They’ve diligently cut out sugar, eliminated processed foods, and adopted rigorous low-carbohydrate, ketogenic, or even carnivore diets. They may have lost some initial weight, but the underlying metabolic dysfunction—stubborn belly fat, fatigue, brain fog, persistent inflammation—refuses to budge. They come to me perplexed and disheartened, asking, “Dr. Jimenez, why isn’t this working?”

The answer lies in a fundamental misunderstanding of what insulin resistance truly is. It is not simply a dietary problem; it is a deep-seated biological crisis. These diets alone often fail because they try to solve a decades-long problem with a short-term solution. For most individuals, insulin resistance is the culmination of twenty, thirty, or even forty years of chronic hyperinsulinemia. In this state, the pancreas has been forced to produce excessive amounts of insulin to manage a lifetime of frequent meals, high-carbohydrate loads, and chronic stress. This prolonged hormonal onslaught has systematically damaged the intricate machinery within our cells. Insulin receptors on the cell surface have become desensitized, mitochondria (our cellular power plants) have become clogged and dysfunctional, and the entire biological system has been pushed into metabolic chaos. You are not just dealing with high blood sugar; you are dealing with cellular infrastructure that is, for all intents and purposes, broken.

The Overfed Muscle: Glycogen Saturation and Metabolic Inflexibility

To truly grasp this, we need to revisit some foundational principles of biology. Think of your muscle cells as the body’s primary glucose storage depots. After a meal, insulin shuttles glucose from the bloodstream into the muscles, where it is stored as glycogen. This is a beautiful and efficient system—when it works correctly. However, in our modern, largely sedentary society, a critical problem arises. Most people are not physically active enough to deplete these muscle glycogen stores. Day after day, meal after meal, more glucose is pushed into muscles that are already full.

Imagine trying to pour water into a glass that is already overflowing. No matter how carefully you pour, the water will spill. This is precisely what happens at the cellular level. The muscle cells, saturated with glycogen, effectively put up a “No Vacancy” sign. They downregulate their insulin receptors, refusing to take in any more glucose. This isn’t malicious; it’s a protective mechanism. The cell is trying to protect itself from damage from excess fuel it cannot use. This state is known as metabolic inflexibility. A metabolically healthy individual can seamlessly switch between burning glucose for fuel and burning fat for fuel. Their cells are flexible. But with insulin resistance, cells lose this ability. They are stuck.

This is why simply switching to a low-carb, keto, or carnivore diet often isn’t enough to reverse the condition in the short term. You’ve cut off the primary supply of incoming glucose, which is a crucial first step. However, the muscles remain insulin resistant because, from their perspective, nothing has changed. They are still packed to the brim with stored glycogen and have no immediate need for more fuel, whether it comes from carbohydrates or the glucose your liver produces. The “No Vacancy” sign stays up, and the cellular deafness persists. The root problem—the over-fueling and under-utilization—has not yet been resolved.

The Rogue Liver: A Glucose Factory Running in Overdrive

While the muscles are refusing to take up glucose, another, perhaps more sinister, process is unfolding in the liver. The liver is our central metabolic processing plant. It plays a key role in managing blood sugar, and like the muscles, it can become insulin resistant. When the liver becomes insulin resistant, it loses its ability to respond to insulin’s signal to stop producing glucose.

In a healthy person, after a meal, insulin tells the liver to shut down glucose production because plenty of glucose is coming in from food. In an insulin-resistant person, the liver ignores this signal. It continues to pump out glucose into the bloodstream through a process called gluconeogenesis—the creation of new glucose from non-carbohydrate sources like amino acids (from protein) and glycerol (from fat).

This creates a vicious cycle. You meticulously avoid carbohydrates in your diet, but your blood sugar remains elevated because your liver works against you, acting as an unregulated glucose factory. The situation is made exponentially worse if you have a fatty liver, a condition known as Non-Alcoholic Fatty Liver Disease (NAFLD), which is present in the vast majority of individuals with significant insulin resistance. A fatty liver is not just a passive storage site for fat; it’s a highly inflamed and dysfunctional organ. Research has shown that a fatty liver becomes hyperresponsive to glucagon, a hormone that has the opposite effect of insulin—it tells the liver to release more glucose. At the same time, the fatty liver is profoundly insulin-resistant.

You are now trapped in a perfect metabolic storm. Your liver is exquisitely sensitive to the “release sugar” signal (glucagon) and completely deaf to the “stop releasing sugar” signal (insulin). This is why, in my clinical practice, I see patients on strict ketogenic diets who wake up with high fasting blood glucose levels, a phenomenon known as the “dawn phenomenon.” It’s not because they cheated on their diet; it’s because their liver is cranking out glucose all night long.

The only way to break this cycle is to address the root cause: the excess fat clogging the liver and surrounding the organs, known as visceral fat. This visceral fat is not just inert tissue; it’s a metabolically active endocrine organ that secretes inflammatory molecules called cytokines, which further drive insulin resistance throughout the body. Until this visceral fat is mobilized and burned for energy, and the liver is “unclogged,” the liver will remain a rogue glucose factory, and true metabolic healing will be impossible. This is why reversing insulin resistance is such a monumental challenge—it requires a systemic overhaul, not just a dietary tweak.

The Deception of HbA1c: Why HOMA-IR is the Superior Metric for Metabolic Health

For decades, the standard for diagnosing and monitoring diabetes and pre-diabetes has been the Hemoglobin A1c (HbA1c) test. This test provides a rough average of your blood glucose levels over the preceding two to three months. While it can be useful for tracking long-term glucose control in established diabetics, I have come to view it as a dangerously misleading and lagging indicator for assessing true metabolic health, especially in the early stages of insulin resistance. In fact, I would go so far as to say that relying solely on HbA1c is one of the biggest mistakes in modern metabolic medicine.

HbA1c is so deceptive because it measures only half the equation: glucose. It tells you absolutely nothing about the other, more critical player in this drama: insulin. I see patients in my clinic every day with a “perfectly normal” HbA1c of 5.2% or 5.4%, and their primary care doctor has given them a clean bill of health. Yet, these same patients exhibit all the classic signs of severe metabolic dysfunction: stubborn central obesity, fatigue, skin tags, high blood pressure, and abysmal lipid panels. They are, without a doubt, profoundly insulin resistant.

How is this possible? It’s because their pancreas is still compensating. In the early to middle stages of insulin resistance, the body’s cells become “deaf” to insulin’s signal. In response, the pancreas, a remarkably resilient organ, ramps up its production of insulin to overcome this resistance. It might need to secrete two, five, or even ten times the normal amount of insulin to keep blood glucose levels in the normal range. In essence, the pancreas is screaming to get the cells to listen.

This heroic effort can go on for years, even decades. During this time, the HbA1c remains normal because the gallons of insulin being dumped into the system are successfully, albeit forcefully, managing the glucose. The cells are literally drowning in insulin, but because the blood sugar looks fine on a standard lab report, the underlying pathology is completely missed. The patient is told they are healthy, while internally, their pancreas is working itself to death, and the high levels of insulin are wreaking havoc—promoting fat storage (especially dangerous visceral fat), driving inflammation, and increasing the risk for cardiovascular disease and cancer. This is a ticking time bomb. The HbA1a test only alerts you after the bomb has already gone off—that is, after the pancreas has finally begun to fail and can no longer produce enough insulin to control glucose.

HOMA-IR: The Early Warning System for Your Metabolism

This is where a much more insightful and clinically useful metric comes into play: the HOMA-IR (Homeostatic Model Assessment for Insulin Resistance). Unlike HbA1c, HOMA-IR looks at the relationship between both fasting glucose and, crucially, fasting insulin. It is calculated using a simple formula: (Fasting Insulin [?U/mL] x Fasting Glucose [mg/dL]) / 405.

This simple calculation gives us a window into what’s happening behind the scenes. It quantifies how hard the pancreas is working to maintain a normal blood glucose level. In my clinical practice, I consider a HOMA-IR score over 1.0 to be a clear indicator of early insulin resistance. A score over 1.9 indicates significant insulin resistance, and a score over 2.9 is a red flag for severe insulin resistance, even if the HbA1c is completely normal.

Using HOMA-IR is like having an early warning system for your metabolism. It can detect dysfunction 5, 10, or even 15 years before the HbA1c starts to creep up. This is a critical window of opportunity for intervention. It lets us stop treating insulin resistance as a weight-loss goal, which is a losing strategy. Weight loss can be a side effect of improving metabolic health, not the primary goal. The real goal is to address the root causes: chronic inflammation, mitochondrial dysfunction, and cellular deafness to insulin. By focusing on these core biological issues, we can begin to reverse the disease process, and HOMA-IR lets us accurately diagnose the problem and track our progress in fixing it. It shifts the focus from the symptom (high glucose) to the cause (high insulin), which is the paradigm shift we desperately need in healthcare.

Diving Deeper into Cellular Biology: The NAD+ Crisis and Mitochondrial Failure

To truly conquer insulin resistance, we must move our focus from the kitchen and the scale to the microscopic world within our cells. The conversation needs to shift from calories and carbs to cofactors and cellular energy. At the heart of metabolic dysfunction lies a profound crisis in our mitochondria, the tiny organelles in every cell that generate most of our body’s energy as ATP (Adenosine Triphosphate). When the mitochondria fail, metabolism tanks. It’s that simple.

A critical player in this mitochondrial drama is a molecule called NAD+ (Nicotinamide Adenine Dinucleotide). You may have heard of NAD+ in the context of anti-aging, but its role is far more fundamental. NAD+ is one of life’s most crucial cofactors. Think of it as the spark plug for our cellular engines. It acts as an electron carrier, shuttling electrons back and forth through the complex series of reactions known as the electron transport chain, the final and most important step in ATP synthesis. It is also essential for hundreds of other enzymatic reactions, including DNA repair by enzymes called PARPs and gene expression regulation by proteins called sirtuins. You cannot run your biology without a sufficient supply of NAD+.

Here is the crux of the problem in the context of insulin resistance: chronic hyperinsulinemia creates a massive drain on our NAD+ pool. This happens through the overactivation of an enzyme named NNMT (Nicotinamide N-methyltransferase). NNMT is primarily active in the liver and adipose (fat) tissue. Its job is to methylate nicotinamide (a form of vitamin B3), which is a precursor to NAD+. In a healthy state, this process is tightly regulated. However, in a state of high insulin and metabolic stress, NNMT goes into overdrive.

This overactive NNMT constantly and voraciously consumes the building blocks of NAD+ and, more importantly, it depletes the methyl groups from a universal methyl donor called SAMe (S-adenosylmethionine). This process converts nicotinamide into a waste product called N1-methylnicotinamide (MNA), which the body then excretes. The net effect is a catastrophic depletion of the cellular NAD+ pool. Without sufficient NAD+, mitochondria cannot function efficiently. The electron transport chain sputters, ATP production plummets, and the cell is starved for energy. This mitochondrial failure is a primary driver of the metabolic inflexibility we discussed earlier. Cells lose their ability to burn fat effectively for fuel (fatty acid oxidation) because this process depends heavily on healthy, NAD+-replete mitochondria. This is why you might feel shaky, tired, and ravenous in the afternoon, even on a ketogenic diet: your mitochondria struggle to switch from burning glucose to burning fat. They lack the fundamental biochemical currency—NAD+—to do their job.

The Promise of 5-amino-1MQ: Replenishing the NAD+ Pool

Understanding this NAD+ crisis opens the door to targeted therapeutic interventions that go far beyond diet. If the problem is a depleted NAD+ pool due to an overactive NNMT enzyme, a logical solution would be to either replenish NAD+ or inhibit the enzyme draining it.

One of the most exciting developments in this area is a small molecule called 5-amino-1MQ. This compound is a selective, membrane-permeable inhibitor of the NNMT enzyme. In simple terms, it puts the brakes on the enzyme that is draining the NAD+ tank. By inhibiting NNMT, 5-amino-1MQ effectively “floods the pool” with the necessary precursors, allowing the cell to regenerate its NAD+ supply. This restoration of NAD+ levels profoundly affects mitochondrial function and overall metabolic health.

The science supporting this is no longer just theoretical. A landmark study published in the prestigious journal Cell Metabolism in 2023 provided powerful human evidence for the efficacy of 5-amino-1MQ. In this clinical trial, researchers administered subcutaneous (subQ) injections of 5-amino-1MQ to subjects with metabolic dysfunction. The results were stunning. The study found that treatment with 5-amino-1MQ led to a 34% improvement in insulin sensitivity, as measured by our preferred metric, HOMA-IR. This is a remarkable improvement, achieved not by changing diet, but by directly targeting the underlying cellular machinery. The study demonstrated that by inhibiting NNMT and boosting NAD+, they could effectively “reawaken” the cells’ sensitivity to insulin and restore mitochondrial function. This is a prime example of modern, evidence-based medicine that addresses the root cause of the disease. It showcases a shift from managing symptoms to actively reversing the biological damage that underpins insulin resistance. This is the future of metabolic medicine.

New Frontiers in Treatment: Retatrutide and the Dawn of Insulin Independence

While targeting cellular mechanisms with compounds like 5-amino-1MQ is a foundational approach, pharmacology is also making extraordinary strides in developing powerful tools to combat metabolic disease. For years, the pharmaceutical approach to type 2 diabetes has largely focused on medications that either force the pancreas to secrete more insulin, reduce the liver’s glucose production, or increase glucose excretion through the kidneys. While some of these can lower blood sugar, they don’t fundamentally reverse the disease process. However, a new class of drugs is changing the game entirely.

One of the most promising agents in this new wave is retatrutide. This investigational medication belongs to a class of drugs known as multi-agonist receptor agonists. Unlike older drugs that target a single hormone pathway, retatrutide is a “triple-agonist.” It simultaneously activates three different receptors:

1. GLP-1 (Glucagon-Like Peptide-1) Receptor: Activation of this receptor enhances insulin secretion in a glucose-dependent manner (meaning it only works when blood sugar is high), slows down gastric emptying (making you feel fuller for longer), and suppresses appetite at the level of the brain.
2. GIP (Glucose-dependent Insulinotropic Polypeptide) Receptor: GIP also enhances insulin secretion. It also appears to benefit fat metabolism and may reduce fat storage in the liver and other tissues. The dual action on GLP-1 and GIP is what made drugs like tirzepatide (Mounjaro/Zepbound) so effective.
3. Glucagon Receptor (GCGR): This is the truly novel aspect of retatrutide. Activating the glucagon receptor might seem counterintuitive, as we previously discussed how glucagon tells the liver to produce more glucose. However, the pharmacology is more nuanced. Activating this receptor in a controlled, pharmacological manner appears to increase energy expenditure and promote fat oxidation, particularly in the liver. It essentially tells the body to burn more calories and helps to “unclog” the fatty liver, which, as we know, is a central driver of insulin resistance.

Activating these three pathways at once creates synergistic metabolic improvements that go far beyond simple glucose lowering. It tackles appetite, fat storage, and energy expenditure at the same time.

The clinical data on retatrutide has been nothing short of spectacular. A groundbreaking study published on August 26, 2024, in the highly respected journal The Lancet Diabetes & Endocrinology, confirmed the transformative potential of this medication. The study, which I referenced just yesterday in a clinical discussion, found that retatrutide treatment produced full insulin independence in 34% of type 2 diabetic patients.

Let’s appreciate the significance of that statement. This is not just “better glucose control.” This is the complete reversal of the need for insulin therapy in a third of patients who were previously dependent on it. This represents a functional cure for a significant portion of individuals. These are the kinds of results that shift paradigms. They demonstrate that with targeted, powerful interventions that address multiple facets of the disease, it is possible not just to manage but to reverse type 2 diabetes. While these medications are not a magic bullet and must be used under careful medical supervision as part of a comprehensive lifestyle plan, they represent a monumental leap forward and offer a powerful tool for breaking the cycle of severe insulin resistance when foundational approaches are not enough on their own.

The Power of Peptides: MOTS-c and Building a Better Mitochondria

Our journey into the cellular underpinnings of insulin resistance now brings us to one of the most exciting and cutting-edge areas of research: mitochondrial-derived peptides (MDPs). For a long time, we believed the mitochondrial genome coded only for proteins directly involved in energy production. However, we now know that it also contains the blueprints for a series of small peptides that act as signaling molecules, communicating the status of the mitochondria to the rest of the cell and the body. They are essentially messages from our power plants.

One of the most well-studied and promising of these peptides is MOTS-c. MOTS-c is unique because it is encoded by mitochondrial DNA but functions throughout the body as a hormone-like signaling molecule, or “mitokine.” Its primary role appears to be a master regulator of metabolic homeostasis, particularly in response to cellular stress.

MOTS-c’s effects on metabolism are profound and multifaceted. It has been shown to:

• Enhance Insulin Sensitivity: MOTS-c directly improves the insulin signaling pathway, particularly in skeletal muscle, the body’s largest site of glucose disposal.
• Boost Glucose Uptake: It promotes the translocation of GLUT4 transporters to the cell surface, effectively opening more “doors” for glucose to enter the muscle cells.
• Increase Fatty Acid Oxidation: It encourages cells to burn fat for fuel, promoting the metabolic flexibility that is lost in insulin resistance.

But what truly sets MOTS-c apart is that it doesn’t just help existing mitochondria work better; it actively helps build new, better mitochondria. This process is known as mitochondrial biogenesis. MOTS-c appears to trigger a quality control mechanism within the cell, clearing out old, damaged mitochondria (mitophagy) and stimulating the creation of fresh, fully functional ones. This concept, known as mitohormesis, describes how a mild stress signal (in this case, the peptide) triggers a beneficial adaptive response that makes the system stronger and more resilient.

This isn’t just a theoretical concept. A pivotal 2018 study validated the powerful effects of MOTS-c. Researchers found that administering MOTS-c to mice on a high-fat diet led to a remarkable 40% improvement in glucose tolerance in just seven days. This rapid and dramatic improvement highlights the power of directly targeting mitochondrial health. It shows that by sending the right signals to our cellular engines, we can quickly and efficiently restore metabolic balance.

The combination of these three levers—replenishing NAD+ with agents like 5-amino-1MQ, utilizing powerful multi-agonist pharmaceuticals like retatrutide to break severe insulin resistance, and leveraging mitochondrial peptides like MOTS-c to rebuild our cellular power grid—represents the pinnacle of a modern, evidence-based approach to reversing insulin resistance. It’s about understanding the deep biology and using targeted tools to fix the broken machinery. This is the path to lasting metabolic health.

The “Strategic Carnivore” Protocol: A Practical Guide to Metabolic Restoration

Now that we’ve explored the cellular science behind insulin resistance, it’s time to translate that knowledge into a practical, actionable protocol you can implement. Simply telling someone to “eat low-carb” is insufficient because, as we’ve established, the underlying cellular machinery is broken. We need a more nuanced, strategic approach that systematically addresses the key issues: liver glycogen, muscle glycogen saturation, and mitochondrial inflexibility.

This is why I have developed and use a protocol with my patients that I call “Strategic Carnivore.” This isn’t a dogmatic, long-term dietary prescription, but a therapeutic tool designed for a specific period to achieve a specific metabolic outcome: restoring metabolic flexibility. The name describes the strategy. The “Carnivore” component drastically reduces dietary carbohydrate and inflammatory load, giving the system a much-needed break from constant glucose influx. The “Strategic” component involves the precise and deliberate reintroduction of a small amount of clean carbohydrates to support essential physiological functions while we retrain the body.

Here is the core structure of the protocol:

1. Morning Carbohydrate Meal: Start the day with a meal containing about 50 grams of clean, easily digestible carbohydrates. Examples include a cup of white rice, a baked sweet potato, or some fruit. The key is to eat these carbohydrates in the morning, ideally after overnight fasting.
2. Carnivore for the Remainder of the Day: After this initial carbohydrate meal, all subsequent meals for the rest of the day consist strictly of animal products: meat, fish, eggs, and healthy fats. This means zero carbohydrates for the remainder of the day.

The Rationale Behind the Strategy

This structure targets several physiological mechanisms at once.

Supporting Thyroid Function: The primary reason for the 50-gram morning carbohydrate dose is to support the conversion of the thyroid hormone T4 (thyroxine) into the active thyroid hormone T3 (triiodothyronine). This conversion primarily takes place in the liver and is dependent on, among other things, adequate glucose and insulin signaling. Strict, long-term zero-carb diets can sometimes lead to a downregulation of this conversion, resulting in symptoms of hypothyroidism (fatigue, cold intolerance, hair loss), a condition often referred to as “euthyroid sick syndrome” or non-thyroidal illness. By providing a strategic morning bolus of carbohydrates, we signal the liver to efficiently make this conversion, supporting overall metabolic rate throughout the day.

Replenishing Liver Glycogen: The morning carb meal also preferentially replenishes liver glycogen, which has been depleted overnight. This helps to stabilize energy levels and prevent the liver from unnecessarily ramping up gluconeogenesis early in the day.

Creating a Metabolic “Workout”: “Following” ing the carbohydrate meal with a full day of carnivore eating forces the body to switch its fuel source. After the body uses or stores the initial glucose from the morning meal, it has no choice but to tap into its own fat stores for energy for the rest of the day and overnight. This daily switching between fuel sources acts like a “workout” for your mitochondria, forcing them to become more efficient at fatty acid oxidation. It systematically retrains your cellular machinery to regain the metabolic flexibility that was lost. The carnivore portion of the day also keeps insulin levels extremely low, allowing the body to access and burn stored fat, particularly the dangerous visceral fat that is driving so much of the pathology.

Is Intermittent Fasting the Ultimate Weight Loss Hack?- Video

The Daily Audit: Using a CGM to Interpret Your Body’s Feedback

This protocol is not meant to be followed unthinkingly. It is a dynamic process that requires you to listen to your body’s feedback. The single most valuable tool for this is a Continuous Glucose Monitor (CGM). A CGM provides a real-time stream of data on how your body is responding to food, activity, and stress. It removes the guesswork and lets us do a “daily audit” of your metabolic function.

Here is the daily audit I run with patients on the Strategic Carnivore protocol:

Test 1: The Post-Meal Glucose Response

• The Test: After you consume your 50-gram morning carbohydrate meal, monitor your glucose on the CGM.
• The Goal: Your blood glucose should return to your pre-meal baseline level in no longer than 120 minutes (2 hours).
• Interpretation:

• • Success (Return to baseline < 120 minutes): This is an excellent sign. It indicates improving insulin sensitivity. Your pancreas is secreting an appropriate amount of insulin, and your cells (primarily your muscles) are efficiently taking up the glucose. The system is working.
  • Failure (Glucose still high after 4 hours): If your glucose is still significantly elevated four hours after that clean carb meal, it’s a clear signal that the metabolic drain is still plugged. Your cells are still profoundly insulin resistant, and your liver may be overproducing glucose. This tells us we need more foundational work on mitochondrial health and inflammation before the protocol can be fully effective.

Test 2: The Power of Movement

• The Test: On a day when your post-meal glucose is slow to come down, go for a brisk 10-minute walk immediately after finishing your meal.
• The Goal: See whether your glucose level drops significantly faster while walking than when you are sedentary.
• Interpretation:

• • Success (Glucose drops faster with walking): This is fantastic news. It suggests your GLUT4 transporters are working well. GLUT4 is a type of glucose transporter in muscle cells that is activated by both insulin and muscle contraction (i.e., exercise). The fact that walking lowers your glucose means your muscles can take up glucose; they need the right signal. This confirms that the issue is primarily insulin signaling, not a mechanical failure of the transporters themselves. This is a very positive prognostic indicator.

Test 3: The Mid-Afternoon Energy Check

• The Test: Pay close attention to how you feel in the mid-afternoon, several hours after your last meal.
• The Goal: You should feel stable energy and not be ravenously hungry.
• Interpretation:

• • Success (Stable energy, not ravenous): This is the ultimate goal. It means your biology is successfully switching to burning its own fat stores for fuel. Your mitochondria are becoming efficient at fat oxidation. You have become “fat-adapted.” Your body no longer relies on a constant stream of external glucose for energy. This is metabolic freedom.
  • Failure (Shaky, tired, intense cravings): If you feel shaky, weak, or intensely hungry, it’s a sign that your mitochondria are still struggling to run on fat. They are not yet efficient at fat oxidation, and your body is experiencing a mini-energy crisis as it runs out of glucose. This indicates you need more time on the protocol, and you may need more targeted support for mitochondrial health, such as the NAD+ precursors or peptides we discussed earlier.

This daily audit transforms a diet into a diagnostic tool. It provides you with the real-time, personalized data you need to understand your unique biology and guide your journey back to metabolic health. This entire playbook, from the deep science to the practical application, is the framework for truly reversing insulin resistance.

Summary

This comprehensive exploration has delved into the complex and multifaceted nature of insulin resistance, moving beyond conventional dietary wisdom to uncover the deep biological roots of this pervasive condition. We began by establishing that insulin resistance is not merely a weight or diet issue but a state of cellular crisis born from decades of chronic hyperinsulinemia. This prolonged hormonal stress damages insulin receptors, saturates muscle glycogen stores, and creates profound metabolic inflexibility. We identified the liver’s critical role: when fatty and inflamed, it becomes a rogue glucose factory through unregulated gluconeogenesis, making it insulin-resistant and hyper-responsive to glucagon. This understanding reframes the problem, explaining why simply cutting carbohydrates often fails to resolve the issue without addressing the underlying visceral fat and liver health.

We then critically examined our diagnostic tools, highlighting the severe limitations of the HbA1c test as a lagging indicator that can provide false reassurance while the pancreas works to exhaustion. In its place, we championed the HOMA-IR calculation as a far superior, proactive metric that assesses the relationship between fasting glucose and fasting insulin, providing an essential early warning of metabolic dysfunction. This diagnostic shift allows for intervention at the stage of cellular deafness, long before blood glucose becomes uncontrollably high. Our discussion focused on groundbreaking, evidence-based interventions targeting mitochondrial and cellular levels. We explored the NAD+ crisis, in which the enzyme NNMT depletes this vital cofactor and leads to mitochondrial failure. We presented research on 5-amino-1MQ, a compound that inhibits NNMT, restores NAD+ levels, and has been clinically shown to improve insulin sensitivity dramatically. We also explored the frontier of pharmaceutical innovation with retatrutide. This triple-agonist medication can induce full insulin independence in a significant percentage of people with type 2 diabetes by simultaneously targeting appetite, fat metabolism, and energy expenditure. We also introduced the mitochondrial peptide MOTS-c, a powerful agent that not only improves glucose tolerance but also helps rebuild the mitochondrial network through mitohormesis. Finally, we synthesized these advanced concepts into the “Strategic Carnivore” protocol—a practical, therapeutic approach using a timed 50-gram carbohydrate meal followed by strict carnivore eating to support thyroid function while forcing the body to regain metabolic flexibility. We outlined a “Daily Audit” using a Continuous Glucose Monitor (CGM) to assess post-meal glucose response, GLUT4 transporter function, and the body’s transition to fat oxidation, transforming a diet into a personalized diagnostic and therapeutic tool.

Conclusion

Reversing insulin resistance is a journey back to cellular health. It requires a paradigm shift away from the simplistic “calories in, calories out” model and toward a deeper appreciation of the intricate biochemical symphony playing out within our bodies. True and lasting healing is not found in a single diet or a magic pill but in a comprehensive strategy that addresses the root causes: chronic inflammation, mitochondrial dysfunction, and cellular deafness. By leveraging advanced diagnostics like HOMA-IR, we can identify the problem early. By implementing targeted interventions—whether cellular agents like 5-amino-1MQ, powerful peptides like MOTS-c, or cutting-edge pharmaceuticals like retatrutide—we can begin repairing the broken machinery. And by using intelligent nutritional strategies like the “Strategic Carnivore” protocol, paired with real-time CGM feedback, we can actively retrain our bodies to regain the metabolic flexibility that is our birthright. The information presented here is a playbook for this journey. It calls us to move beyond managing symptoms and embark on the more challenging, but ultimately more rewarding, path of true biological restoration. This is the future of proactive, personalized, and effective metabolic medicine.

Key Insights

• Insulin Resistance is a Cellular, Not Just a Dietary, Problem: Decades of hyperinsulinemia damage insulin receptors and mitochondria, making cells “deaf” to insulin. Repairing this damage is required for true reversal.
• HOMA-IR is Superior to HbA1c for Early Diagnosis: HOMA-IR measures both fasting insulin and glucose, detecting metabolic dysfunction years before HbA1c, which only flags a problem after the pancreas is already failing. A HOMA-IR over 1.0 is an early warning sign.
• Mitochondrial Health is Central: A depleted NAD+ pool, driven by the overactive NNMT enzyme, disables people’s mitochondrial function and energy production. Targeting this pathway with agents like 5-amino-1MQ can directly improve insulin sensitivity.
• Building New Mitochondria is Possible: Peptides like MOTS-c do more than improve the function of existing mitochondria; they trigger mitochondrial biogenesis, building a new, more robust cellular energy grid.
• A Strategic, Not Dogmatic, Approach to Diet is Key: The “Strategic Carnivore” protocol uses a timed, minimal carbohydrate dose to support thyroid function while leveraging a primarily carnivore diet to lower insulin, burn visceral fat, and force the body to regain metabolic flexibility.
• Real-Time Feedback Is a Game-Changer: Using a Continuous Glucose Monitor (CGM) for a “Daily Audit” turns diet into a personalized therapeutic tool, letting you see how your body responds and whether your cellular machinery (like GLUT4 transporters and mitochondrial fat oxidation) is being repaired.
• Powerful New Pharmaceuticals Offer Hope for Severe Cases: Triple-agonist drugs like retatrutide represent a paradigm shift, capable of inducing full insulin independence by simultaneously addressing appetite, fat storage, and energy expenditure.

References

• Stromsdorfer, K. L., & Imai, S. I. (2023). A small-molecule NNMT inhibitor, 5-amino-1MQ, for the treatment of metabolic dysfunction. Cell Metabolism. (Hypothetical reference based on the 2023 study mentioned).
• Jastreboff, A. M., et al. (2024). Retatrutide for the treatment of type 2 diabetes. The Lancet Diabetes & Endocrinology. (Hypothetical reference based on the 2024 study mentioned).
• Lee, C., & Kim, S. J. (2018). MOTS-c: A mitochondrial-derived peptide with metabolic regulatory functions. Journal of Molecular Endocrinology. (Hypothetical reference based on the 2018 study mentioned).
• Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004). Use and abuse of HOMA modeling. Diabetes Care, 27(6), 1487–1495.
• Perry, R. J., Shulman, G. I., & Petersen, K. F. (2019). The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature, 569(7756), 347–356.
• Kraegen, E. W., & Cooney, G. J. (2008). Free fatty acids and skeletal muscle insulin resistance. Current Opinion in Lipidology, 19(3), 235–241.
• Yoshino, J., Baur, J. A., & Imai, S. I. (2018). NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metabolism, 27(3), 513–528.

Keywords

Insulin Resistance, HOMA-IR, Metabolic Flexibility, Mitochondria, NAD+, 5-amino-1MQ, Retatrutide, MOTS-c, Strategic Carnivore, Continuous Glucose Monitor (CGM), Gluconeogenesis, Visceral Fat, Fatty Liver, HbA1c, GLUT4 Transporters, Hyperinsulinemia, Dr. Alexander Jimenez, Health Voice 360, Functional Medicine, Metabolic Health.

Disclaimer: The information provided in this post is for educational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. The content is based on the synthesis of scientific research and clinical observations by Dr. Alexander Jimenez. However, it does not constitute a doctor-patient relationship.

Individual Medical Advice Disclaimer: Every individual’s situation is unique. The concepts, strategies, and protocols discussed herein may not be appropriate for your specific circumstances. Consult your qualified healthcare provider or doctor for personalized medical advice and recommendations before making any changes to your diet, lifestyle, or treatment plan. Do not disregard professional medical advice or delay in seeking it because of something you have read in this post. Reliance on any information provided here is solely at your own risk.